by matt | Sep 19, 2023 | Emails
Permanent J-Code for REZZAYO™ (rezafungin for injection): Effective October 1, 2023. REZZAYO™ (rezafungin for injection) is an echinocandin antifungal indicated in patients 18 years of age or older who have limited or no alternative options for the treatment of...
by matt | Sep 15, 2023 | Emails
New Indication for Bardet-Biedl syndrome (BBS) Effective October 1, 2023 On September 5, Rhythm issued a press release announcing the new ICD-10-CM code specific to Bardet-Biedl syndrome (BBS) ‒ Q87.83 ‒ effective October 1, 2023. Read Rhythm Press Release This new...
by matt | Sep 13, 2023 | Emails
Safely Treating Molluscum Using YCANTH FDA Consumer Update Safely Treating Molluscum Using YCANTH™Recommendation Issued by the FDA The FDA has issued two consumer updates since June 2023, focusing on the management of Molluscum Contagiosum. The first FDA alert was...
by matt | Sep 13, 2023 | Emails
Now Approved: APHEXDA™ (motixafortide) for injection NOW APROVED: APHEXDATM (motixafortide) for injection APHEXDA™ is indicated in combination with filgrastim (G-CSF) to mobilizehematopoietic stem cells to the peripheral blood forcollection and subsequent...
by matt | Sep 7, 2023 | Emails
Announcing the approval of EYLEA® HD (aflibercept) Injection 8 MG Effective August 18, 2023 Effective August 18th, 2023EYLEA® HD (aflibercept) Injection 8 MG has been approved as a new single source drug by the FDA Suggested Billing and Coding for EYLEA HD** HCPCS...
by matt | Sep 7, 2023 | Emails
Permanent J-Code for SYFOVRE® (pegcetacoplan injection) Effective October 1, 2023 Email content sponsored by Apellis Pharmaceuticals, Inc. Email content sponsored by Apellis Pharmaceuticals, Inc. Effective for claims on and after October 1, 2023:J2781 SYFOVRE...
